CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

JOURNAL ARTICLE published April 2016 in Annals of Oncology

Authors: E.G. Chiorean | D.D. Von Hoff | M. Reni | F.P. Arena | J.R. Infante | V.G. Bathini | T.E. Wood | P.N. Mainwaring | R.T. Muldoon | P.R. Clingan | V. Kunzmann | R.K. Ramanathan | J. Tabernero | D. Goldstein | D. McGovern | B. Lu | A. Ko